医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Tiangen, Qiagen and Life Technologies Emerge as Leading Suppliers in Chinese Nucleic Acid Purification Market According to Percepta

2013年04月30日 PM07:25
このエントリーをはてなブックマークに追加


 

CARLSBAD, Calif.

Percepta Associates announces release of its Series One Nucleic Acid Purification (China) Life Science Dashboard™ market research report revealing Tiangen, Qiagen and Life Technologies as leading suppliers. Fifteen nucleic acid purification (NAP) market segments analyzed in this report include: DNA/RNA library prep for next generation sequencing, RNA/DNA isolation from cells or tissue, whole blood and FFPE samples, plasmid DNA prep, mRNA, microRNA, gel extraction and post-reaction cleanup. Six additional companies emerged as second-tier NAP suppliers: Corning/Axygen, BioTeke, Illumina, Promega, Roche and TaKaRa/Clontech.

“Major differences exist in the Chinese NAP research market such as the competitive landscape, distribution/dealer channels, percent usage by customers, and propensity to switch suppliers for 15 product segments analyzed,” said Cijian Feng, Market Research Associate for East Asia. “We do not see anywhere near the same level of market entrenchment in China for suppliers like Qiagen, Life Technologies and Illumina as we observe in the US or Europe.”

Designed and executed by individuals with practical industry experience, this report contains strategically grounded findings and recommendations that simplify business planning and guide you in a more competitive direction into important and emerging market segments with confidence and certainty.

Findings are based on survey responses obtained from 449 academic and commercial research scientists predominantly located in China from our leading proprietary panel of active life scientists. Key market indicators for each of 15 product segments detailed in the report include:

  • Market Opportunity Matrix
  • Percent of purchases direct from supplier versus distributor
  • Overall and segment market sizes & market growth rates
  • Share of mentions for primary kit supplier
  • Reaction throughput rates
  • Customer satisfaction & propensity to switch suppliers
  • Competitive landscape*
  • Perceived pricing
  • Technique usage frequency
  • Research focus and target of NAP experiments
  • Desired product changes

*Companies cited by respondents in this report include:

  • Affymetrix/USB (NASDAQ: AFFX)
  • Agilent/Stratagene (NASDAQ: A)
  • Aidlab
  • Beyotime
  • Bioer
  • Biomiga
  • BioTeke
  • Corning/Axygen (NASDAQ: GLW)
  • CW Bio
  • Daan Gene
  • Diagenode
  • Dingguo
  • Dongsheng
  • Formosa Biomedical
  • Fermentas
  • GE Healthcare (NASDAQ: GE)
  • Geneaid
  • Generay
  • Illumina/Epicentre (NASDAQ: ILMN)
  • Life Technologies/Invitrogen/Ambion (NASDAQ: LIFE)
  • Lifefeng
  • Macherey Nagel
  • Millipore
  • Omega Bio-Tek
  • Promega
  • Qiagen/SABiosciences (NASDAQ: QGEN)
  • Roche Applied Science (ROG: SIX Swiss Ex)
  • Sangon
  • Shanghai ZJ
  • Sigma Aldrich (NASDAQ: SIAL)
  • TaKaRa Bio Inc (4974 Tokyo)
  • Thermo Fisher (NASDAQ: TMO)
  • Tiangen
  • TransGen
  • Vigorous
  • Zymo Research

To view the 2013 Series One Nucleic Acid Purification (China) Life Science DashboardTM sample data and questionnaire, please click here.

About Percepta

Founded in 2005 in Carlsbad, California Percepta is a specialized consultancy providing market assessment, product development and pricing, brand assessment and development, market planning, ad concept and message testing and due diligence services to life science research suppliers globally. For more information visit: www.perceptaassociates.com or call 877 597 9236.

CONTACT

Percepta Associates Inc.
Anne St Louis, Director
877-597-9236
AStlouis@perceptaassociates.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表